Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Anders Widmark(Umeå University), Sophie D. Fosså(Oslo University Hospital)
Cited by 873
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
|JNCI Journal of the National Cancer Institute|2005|830
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
|Journal of Clinical Oncology|2001|628
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
|The Lancet Oncology|2014|491
Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
|Journal of Clinical Oncology|2007|348